MarketResearchFuture.com adds “Nephroblastoma Treatment Market -2017 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023” reports to its database.
Market Scenario of Global Nephroblastoma Treatment Market:
Nephroblastoma also known as Wilms’ Tumor is a rare type of malignant kidney cancer generally found in children mostly under the age of seven. It occurs during the embryonic stage, where it develops from immature kidney cells which are involved in the child’s kidney while they are present in the womb. At the time of birth, the cells usually disappear, but in some cases primitive kidney cell clusters can persist, giving way to this condition. This condition is characterised by abnormalities of the genitals known as hemihypertrophy. According to NCBI, nephroblastoma appears as childhood renal tumor, accounting for about 6% of all pediatric malignancies. It predominantly affects children less than five years of age, with 90% of cases diagnosed before age of three years.
Over the last 25 years, the treatment of nephroblastoma has made great progress. Surgery, chemotherapy and sometimes radiation therapy is used for the treatment of nephroblastoma. Treatments vary according to the stage of cancer. Nephroblastoma treatment market is growing due to the increasing incidence of new-born, technological advancement in therapies is acting as a driving force for the global nephroblastoma treatment market.
Furthermore, macro-economic factors such as increasing expenditure on research and development to develop novel therapies for nephroblastoma will drive this market in forecast period. On the other hand, lack of skilled healthcare professionals, rich experience in using these advanced technologies, high cost associated with the diagnosis and treatment procedure are expected to act as a restrains to the nephroblastoma treatment market.
Key Players for Global Nephroblastoma Treatment Market:
Some of key the players in the global nephroblastoma treatment market are Bayer HealthCare LLC (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Sanofi Pasteur Inc. (U.S.), Merck & Co. Inc. (U.S.), MediLexicon International Ltd (U.S.), Bristol-Myers Squibb Company (U.S.), Apotex Inc. (U.S.), and others.
Segmentation of Global Nephroblastoma Treatment Market:
The nephroblastoma treatment is segmented on the basis of types, drugs, diagnosis, treatment, distribution channel, and end-users.
On the basis of the types, the market is segmented into favorable histology, unfavorable histology (anaplastic Wilms tumor).
On the basis of the drugs, the market is segmented into dactinomycin (cosmegen), doxorubicin (adriamycin), vincristine (vincasar pfs, oncovin), cyclophosphamide (cytoxan, neosar), etoposide (toposar, vepesid), irinotecan (camptosar) and others.
On the basis of the diagnosis, the market is segmented into ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI), chest x-ray, bone scan, lab tests and others.
On the basis of the treatment, the market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery is classified into radical nephrectomy, partial nephrectomy (nephron-sparing surgery) and others.
On the basis of the distribution channel, the market is segmented into hospital pharmacies, e-commerce, drug stores, retail pharmacy, and others.
On the basis of the end-user, the market is segmented into hospitals, cancer centers, surgical centers and ambulatory surgical center.
GET SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/5229 .
Regional Analysis of Global Nephroblastoma Treatment Market:
The global nephroblastoma treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is projected to hold the largest share of the global nephroblastoma treatment market. Analyzing the present scenario North America dominates the global market for nephroblastoma followed by Europe due to the high incidence rate of nephroblastoma. According to the American Society of Cancer in 2015, about 500 new cases of nephroblastoma were diagnosed in the U.S.
Europe is expected to capture the second lead in this market in the coming five years owing to factors such as increasing demand for diagnostic solutions and treatment therapies for nephroblastoma, substantial technological advancements. The European nephroblastoma market is expected to have a tremendous growth during the forecast period
The market in the Asia Pacific is also expected to witness the fastest growth rate within the forecast period due to the high birth rate. As nephroblastoma is the most common renal malignancy in children. The five-year overall survival rates have dramatically improved to approximately 90% with multimodal therapy. The Middle East and Africa are also expected to show a healthy growth in the coming five years due to the disease prevalence, which is relatively more in the African countries while comparatively less in East Asia.
Major TOC of Nephroblastoma Treatment Market:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Global Nephroblastoma Treatment Market, By Types
Chapter 7. Global Nephroblastoma Treatment Market, By Drug
Chapter 8. Global Nephroblastoma Treatment Market, By Diagnosis
Chapter 9. Global Nephroblastoma Treatment Market, By Treatment
Chapter 10. Global Nephroblastoma Treatment Market, By Distribution Channel
Chapter 11. Global Nephroblastoma Treatment Market, By End User
Chapter 12. Global Nephroblastoma Treatment Market, By Region
Chapter 13. Company Landscape
Chapter 14. Company Profiles
Chapter 16. Appendix
GET DISCOUNT @ https://www.marketresearchfuture.com/check-discount/5229 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email: akash.anand@marketresearchfuture.com
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/nephroblastoma-treatment-market-5229